{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:52:54Z","timestamp":1768387974691,"version":"3.49.0"},"reference-count":108,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IPO Porto","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"IPO Porto","award":["LPCC-NRN2023-BVN"],"award-info":[{"award-number":["LPCC-NRN2023-BVN"]}]},{"name":"IPO Porto","award":["LPCC-NRN2025-VT"],"award-info":[{"award-number":["LPCC-NRN2025-VT"]}]},{"DOI":"10.13039\/501100011733","name":"Portuguese League Against Cancer\u2014Northern Branch","doi-asserted-by":"publisher","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}],"id":[{"id":"10.13039\/501100011733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011733","name":"Portuguese League Against Cancer\u2014Northern Branch","doi-asserted-by":"publisher","award":["LPCC-NRN2023-BVN"],"award-info":[{"award-number":["LPCC-NRN2023-BVN"]}],"id":[{"id":"10.13039\/501100011733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011733","name":"Portuguese League Against Cancer\u2014Northern Branch","doi-asserted-by":"publisher","award":["LPCC-NRN2025-VT"],"award-info":[{"award-number":["LPCC-NRN2025-VT"]}],"id":[{"id":"10.13039\/501100011733","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["LPCC-NRN2023-BVN"],"award-info":[{"award-number":["LPCC-NRN2023-BVN"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["LPCC-NRN2025-VT"],"award-info":[{"award-number":["LPCC-NRN2025-VT"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cervical cancer (CC) is the fourth most common cancer among women globally, with venous thromboembolism (VTE) representing a life-threatening complication. Cancer-associated thrombosis (CAT) arises from tumor-driven activation of hemostasis, worsening prognosis. Recently, circulating microRNAs (miRNAs) have emerged as potential biomarkers for both CAT and cervical tumorigenesis. Thus, this study aimed to assess the implications of five miRNAs\u2014miR-20a-5p, -23a-3p, -125b-5p, -145-5p, and -616-3p\u2014in CC-related VTE context. These miRNAs were quantified by RT-qPCR in plasma from 69 CC patients before treatment. Briefly, VTE occurred in nine patients, decreasing overall survival (OS) [log-rank test, p = 0.005; hazard ratio (HR) = 4.78; 95% confidence interval (CI), 1.42\u201316.05]. Lower miR-20a-5p levels predicted VTE (\uab532 test, p = 0.027) and, in subgroup analyses, they were linked to cervical squamous cell carcinoma (CSCC) and older age (\uab532 test, p = 0.003 and p = 0.043, respectively). In VTE patients, miR-145-5p downregulation was associated with improved OS (log-rank test, p = 0.018), an effect also observed in the adenocarcinoma (ADC) subgroup (log-rank test, p = 0.039). The remaining miRNAs showed subtype-specific links to clinicopathological features and survival. These findings highlight the potential value of circulating miRNAs in thrombotic risk and prognosis assessment in CC.<\/jats:p>","DOI":"10.3390\/ijms26199796","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:06:53Z","timestamp":1759932413000},"page":"9796","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Venous Thrombogenesis and Cervical Cancer: Plasma MicroRNAs as Prognostic Indicators of Tumor Behavior"],"prefix":"10.3390","volume":"26","author":[{"given":"Mariana Teixeira","family":"Costa","sequence":"first","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Pathology and Laboratory Medicine Department\/Clinical Pathology\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"CytoGenomics Lab, Department of Genetics and Biotechnology, University of Tr\u00e1s-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal"}]},{"given":"Beatriz Vieira","family":"Neto","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Pathology and Laboratory Medicine Department\/Clinical Pathology\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0181-5354","authenticated-orcid":false,"given":"Jos\u00e9 Brito","family":"da Silva","sequence":"additional","affiliation":[{"name":"Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"given":"Lu\u00edsa","family":"Carvalho","sequence":"additional","affiliation":[{"name":"External Radiotherapy Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"given":"Lurdes","family":"Salgado","sequence":"additional","affiliation":[{"name":"External Radiotherapy Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[{"name":"Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"given":"Filomena","family":"Adega","sequence":"additional","affiliation":[{"name":"CytoGenomics Lab, Department of Genetics and Biotechnology, University of Tr\u00e1s-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal"},{"name":"Biosystems and Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-7757","authenticated-orcid":false,"given":"Val\u00e9ria","family":"Tavares","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Pathology and Laboratory Medicine Department\/Clinical Pathology\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Pathology and Laboratory Medicine Department\/Clinical Pathology\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal"},{"name":"Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, 4050-313 Porto, Portugal"},{"name":"Biomedical Research Center (CEBIMED), Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"322","article-title":"Global Burden of Cervical Cancer: Current Estimates, Temporal Trend and Future Projections Based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Salarzaei, M., van de Laar, R.L.O., Ewing-Graham, P.C., Najjary, S., van Esch, E., van Beekhuizen, H.J., and Mustafa, D.A.M. (2024). Unraveling Differences in Molecular Mechanisms and Immunological Contrasts between Squamous Cell Carcinoma and Adenocarcinoma of the Cervix. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25116205"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Na, J., Li, Y., Wang, J., Wang, X., Lu, J., and Han, S. (2023). The Correlation between Multiple HPV Infections and the Occurrence, Development, and Prognosis of Cervical Cancer. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1220522"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ygyno.2021.10.007","article-title":"Clinicopathological Characteristics and Prognosis of Cervical Cancer with Different Histological Types: A Population-Based Cohort Study","volume":"163","author":"Meng","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, X., Lv, Z., Xu, X., Yin, Z., and Lou, H. (2020). Comparison of Adenocarcinoma and Adenosquamous Carcinoma Prognoses in Chinese Patients with FIGO Stage IB-IIA Cervical Cancer Following Radical Surgery. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07148-x"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.3802\/jgo.2020.31.e80","article-title":"Does Adenocarcinoma Have a Worse Prognosis than Squamous Cell Carcinoma in Patients with Cervical Cancer? A Real-World Study with a Propensity Score Matching Analysis","volume":"31","author":"Pan","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12672-022-00551-9","article-title":"Exploration of Biomarkers for the Diagnosis, Treatment and Prognosis of Cervical Cancer: A Review","volume":"13","author":"Arip","year":"2022","journal-title":"Discov. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cca.2015.03.005","article-title":"Cervical Cancer: Biomarkers for Diagnosis and Treatment","volume":"445","author":"Dasari","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1097\/IGC.0000000000001111","article-title":"Venous Thromboembolism in Gynecological Malignancy","volume":"27","author":"Cohen","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism Is a Leading Cause of Death in Cancer Patients Receiving Outpatient Chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"180119","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-Associated Thrombosis: The When, How and Why","volume":"28","author":"Fernandes","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.thromres.2021.12.008","article-title":"Cancer Genetic Alterations and Risk of Venous Thromboembolism","volume":"213","author":"Mantha","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103782","DOI":"10.1016\/j.critrevonc.2022.103782","article-title":"Venous Thromboembolism in Cancer and Cancer Immunotherapy","volume":"178","author":"Kacimi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Neto, B.V., Tavares, V., da Silva, J.B., Liz-Pimenta, J., Marques, I.S., Carvalho, L., Salgado, L., Pereira, D., and Medeiros, R. (2023). Thrombogenesis-Associated Genetic Determinants as Predictors of Thromboembolism and Prognosis in Cervical Cancer. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-36161-w"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2009.01.021","article-title":"Thromboembolic Events in Patients with Cervical Carcinoma: Incidence and Effect on Survival","volume":"113","author":"Jacobson","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1076029620954282","DOI":"10.1177\/1076029620954282","article-title":"Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management","volume":"26","author":"Hamza","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_19","first-page":"6S3","article-title":"Epidemiology and Risk Factors for Cancer-Associated Thrombosis","volume":"45","author":"Sevestre","year":"2020","journal-title":"J. Med. Vasc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12672-022-00610-1","article-title":"Map of Thrombogenesis in Viral Infections and Viral-Driven Tumours","volume":"14","author":"Neto","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Scridon, A. (2022). Platelets and Their Role in Hemostasis and Thrombosis\u2014From Physiology to Pathophysiology and Therapeutic Implications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112772"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pablo-Moreno, J.A.D., Serrano, L.J., Revuelta, L., S\u00e1nchez, M.J., and Liras, A. (2022). The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158283"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.mpaic.2007.02.008","article-title":"Haemostasis, Blood Platelets and Coagulation","volume":"8","author":"Minors","year":"2007","journal-title":"Anaesth. Intensive Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New Fundamentals in Hemostasis","volume":"93","author":"Versteeg","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mpaic.2015.11.004","article-title":"Physiology of Haemostasis","volume":"17","author":"Sira","year":"2016","journal-title":"Anaesth. Intensive Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hiller, E. (2007). Basic Principles of Hemostasis. Modern Hematology, Humana Press.","DOI":"10.1007\/978-1-59745-149-9_19"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the Control of Blood Coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"key":"ref_28","first-page":"2041","article-title":"Hemostasis and Endothelial Functionality: The Double Face of Coagulation Factors","volume":"109","author":"Olgasi","year":"2024","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tavares, V., Neto, B.V., Marques, I.S., Assis, J., Pereira, D., and Medeiros, R. (2024). Cancer-Associated Thrombosis: What about MicroRNAs Targeting the Tissue Factor Coagulation Pathway?. Biochim. Biophys. Acta Rev. Cancer, 1879.","DOI":"10.1016\/j.bbcan.2023.189053"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31647","DOI":"10.1074\/jbc.M114.569665","article-title":"Platelets Contain Tissue Factor Pathway Inhibitor-2 Derived from Megakaryocytes and Inhibits Fibrinolysis","volume":"289","author":"Vadivel","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/mco.2021.2479","article-title":"Tissue Factor Pathway Inhibitor 2 as a Serum Marker for Diagnosing Asymptomatic Venous Thromboembolism in Patients with Epithelial Ovarian Cancer and Positive D-Dimer Results","volume":"16","author":"Miyake","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"111561","DOI":"10.1016\/j.isci.2024.111561","article-title":"Transcriptomic Profiling of LncRNAs and MRNAs in a Venous Thrombosis Mouse Model","volume":"28","author":"Hao","year":"2025","journal-title":"iScience"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Palanichamy, J.K., and Rao, D.S. (2014). MiRNA Dysregulation in Cancer: Towards a Mechanistic Understanding. Front. Genet., 5.","DOI":"10.3389\/fgene.2014.00054"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Toden, S., Zumwalt, T.J., and Goel, A. (2021). Non-Coding RNAs and Potential Therapeutic Targeting in Cancer. Biochim. Biophys. Acta Rev. Cancer, 1875.","DOI":"10.1016\/j.bbcan.2020.188491"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Morelli, V.M., Br\u00e6kkan, S.K., and Hansen, J.B. (2020). Role of MicroRNAs in Venous Thromboembolism. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072602"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating MicroRNAs as Stable Blood-Based Markers for Cancer Detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jth.12788","article-title":"MicroRNAs in Hemostasis","volume":"13","author":"Rosendaal","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MOH.0000000000000424","article-title":"MicroRNAs in Endothelial Cell Homeostasis and Vascular Disease","volume":"25","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","article-title":"User\u2019s Guide to Correlation Coefficients","volume":"18","author":"Akoglu","year":"2018","journal-title":"Turk. J. Emerg. Med."},{"key":"ref_41","first-page":"69","article-title":"Statistics Corner: A Guide to Appropriate Use of Correlation Coefficient in Medical Research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Med. J."},{"key":"ref_42","first-page":"2008","article-title":"Spearman\u2019s Correlation Coefficient in Statistical Analysis","volume":"13","author":"Ali","year":"2022","journal-title":"Int. J. Nonlinear Anal. Appl."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5482\/ha-1160","article-title":"Crosstalk between Cancer and Haemostasis: Implications for Cancer Biology and Cancer-Associated Thrombosis with Focus on Tissue Factor","volume":"32","author":"Langer","year":"2012","journal-title":"Hamostaseologie"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1055\/s-0039-1693472","article-title":"Cancer-Associated Thrombosis: A Two-Way Street","volume":"45","author":"Sharma","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/gyno.2001.6452","article-title":"The Clinical Course of Deep Vein Thrombosis in Patients with Gynecologic Cancer","volume":"84","author":"Morgan","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/LGT.0000000000000231","article-title":"Biomarkers for Cervical Cancer Prevention Programs: The Long and Winding Road From Discovery to Clinical Use","volume":"20","author":"Wentzensen","year":"2016","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hassan, N., Efing, J., Kiesel, L., Bendas, G., and G\u00f6tte, M. (2023). The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans. Cancers, 15.","DOI":"10.3390\/cancers15051524"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ebiom.2017.11.022","article-title":"MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis","volume":"26","author":"Sahu","year":"2017","journal-title":"eBioMedicine"},{"key":"ref_49","first-page":"53","article-title":"MicroRNA-23a Acts as an Oncogene in Pancreatic Carcinoma by Targeting TFPI-2","volume":"20","author":"Wang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kobayashi, H., Shigetomi, H., and Imanaka, S. (2025). Reassessing the Role of Tissue Factor Pathway Inhibitor 2 in Neoplastic and Non-Neoplastic Lesions. Cancers, 17.","DOI":"10.3390\/cancers17091447"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s10555-024-10205-7","article-title":"Tissue Factor Pathway Inhibitor-2 (TFPI-2)\u2014An Underappreciated Partaker in Cancer and Metastasis","volume":"43","author":"Wojtukiewicz","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Full\u00e1r, A., Kar\u00e1szi, K., Holl\u00f3si, P., Lendvai, G., Ol\u00e1h, L., Reszegi, A., Papp, Z., Sobel, G., Dud\u00e1s, J., and Kovalszky, I. (2020). Two Ways of Epigenetic Silencing of TFPI2 in Cervical Cancer. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234873"},{"key":"ref_53","first-page":"419","article-title":"Dual Role of Tissue Factor Pathway Inhibitor 2\u2014A Novel Serodiagnostic Marker for Ovarian Cancer\u2014In Human Cancers","volume":"4","author":"Kobayashi","year":"2024","journal-title":"Int. J. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-9966-31-1","article-title":"Reduced Expression of Tissue Factor Pathway Inhibitor-2 Contributes to Apoptosis and Angiogenesis in Cervical Cancer","volume":"31","author":"Zhang","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/0300060517709614","article-title":"Plasma MiR-145 as a Novel Biomarker for the Diagnosis and Radiosensitivity Prediction of Human Cervical Cancer","volume":"45","author":"Wei","year":"2017","journal-title":"J. Int. Med. Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Tavares, V., Savva-Bordalo, J., Rei, M., Liz-Pimenta, J., Assis, J., Pereira, D., and Medeiros, R. (2024). Plasma MicroRNA Environment Linked to Tissue Factor Pathway and Cancer-Associated Thrombosis: Prognostic Significance in Ovarian Cancer. Biomolecules, 14.","DOI":"10.3390\/biom14080928"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1076397","DOI":"10.1155\/2017\/1076397","article-title":"MiR-19a and MiR-20a and Tissue Factor Expression in Activated Human Peripheral Blood Mononuclear Cells","volume":"2017","author":"Balia","year":"2017","journal-title":"Thrombosis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2011.04451.x","article-title":"Identification of MiRNAs as Potential Modulators of Tissue Factor Expression in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome","volume":"9","author":"Teruel","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e23094","DOI":"10.1002\/jcla.23094","article-title":"MiR-125b but Not MiR-125a Is Upregulated and Exhibits a Trend to Correlate with Enhanced Disease Severity, Inflammation, and Increased Mortality in Sepsis Patients","volume":"34","author":"Zhu","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopha.2016.03.041","article-title":"MiR-128 and MiR-125 Regulate Expression of Coagulation Factor IX Gene with Nonsense Mutation by Repressing Nonsense-Mediated MRNA Decay","volume":"80","author":"Wang","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s11033-013-2998-0","article-title":"MicroRNAs as Biomarkers of Cervical Cancer Development: A Literature Review on MiR-125b and MiR-34a","volume":"41","author":"Ribeiro","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Choi, P.W., Liu, T.L., Wong, C.W., Liu, S.K., Lum, Y.L., and Ming, W.K. (2022). The Dysregulation of MicroRNAs in the Development of Cervical Pre-Cancer\u2014An Update. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137126"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1007\/s13277-014-3009-3","article-title":"Downregulation of MicroRNA-145 Is Associated with Aggressive Progression and Poor Prognosis in Human Cervical Cancer","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.7314\/APJCP.2013.14.4.2289","article-title":"Aberrant Expression of MiR-20a and MiR-203 in Cervical Cancer","volume":"14","author":"Zhao","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhao, S., Yao, D., Chen, J., Ding, N., and Ren, F. (2015). MiR-20a Promotes Cervical Cancer Proliferation and Metastasis in Vitro and in Vivo. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120905"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1474-9726.2010.00549.x","article-title":"MiR-17, MiR-19b, MiR-20a, and MiR-106a Are down-Regulated in Human Aging","volume":"9","author":"Hackl","year":"2010","journal-title":"Aging Cell"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Derouet, M.F., Liu, G., and Darling, G.E. (2014). MiR-145 Expression Accelerates Esophageal Adenocarcinoma Progression by Enhancing Cell Invasion and Anoikis Resistance. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115589"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Derouet, M.F., Dakpo, E., Wu, L., Zehong, G., Conner, J., Keshavjee, S., de Perrot, M., Waddell, T., Elimova, E., and Yeung, J. (2018). MiR-145 Expression Enhances Integrin Expression in SK-GT-4 Cell Line by down-Regulating c-Myc Expression. PLoS ONE, 9.","DOI":"10.18632\/oncotarget.24613"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Chen, F., Chen, L., Zhang, Y., Shi, L., Xu, H., and Song, T. (2022). Survival Comparison Between Squamous Cell Carcinoma and Adenocarcinoma for Radiotherapy-Treated Patients with Stage IIB-IVA Cervical Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.895122"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s10147-017-1225-8","article-title":"A Comparison of the Prognosis between Adenocarcinoma and Squamous Cell Carcinoma in Stage IB\u2013IIA Cervical Cancer","volume":"23","author":"Xie","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3390\/curroncol29070372","article-title":"Molecular Differences between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers","volume":"29","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/2211536607666180629155025","article-title":"Functional Role of MicroRNA-23b-3p in Cancer Biology","volume":"7","author":"Grossi","year":"2018","journal-title":"MicroRNA"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hou, Y., Zhang, L., Wang, W., Cheng, K., Wang, H., Ji, Y., Su, X., and Hao, M. (2025). Down-Regulation of MiR-125b by HPV16 E6 Might Promote Cervical Cancer Progression through TAZ\/TEAD. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1444874"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mei, L.L., Wang, W.J., Qiu, Y.T., Xie, X.F., Bai, J., and Shi, Z.Z. (2017). MiR-125b-5p Functions as a Tumor Suppressor Gene Partially by Regulating HMGA2 in Esophageal Squamous Cell Carcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185636"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2152\/jmi.62.154","article-title":"Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical Cancer","volume":"62","author":"Saijo","year":"2015","journal-title":"J. Med. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1161\/01.ATV.0000248731.55781.87","article-title":"Tissue Factor Pathway Inhibitor-2 Is Upregulated by Vascular Endothelial Growth Factor and Suppresses Growth Factor-Induced Proliferation of Endothelial Cells","volume":"26","author":"Xu","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Pi\u0161kur, I., Topolovec, Z., Bakula, M., Zagorac, I., Mili\u0107 Vranje\u0161, I., and Vidosavljevi\u0107, D. (2023). Expression of Vascular Endothelial Growth Factor-A (VEGF-A) in Adenocarcinoma and Squamous Cell Cervical Cancer and Its Impact on Disease Progression: Single Institution Experience. Medicina, 59.","DOI":"10.3390\/medicina59071189"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"Figo\u2019s Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication","volume":"26","author":"Prat","year":"2015","journal-title":"J. Gynecol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3892\/ijmm.2013.1424","article-title":"Serum MicroRNA Expression Levels Can Predict Lymph Node Metastasis in Patients with Early-Stage Cervical Squamous Cell Carcinoma","volume":"32","author":"Chen","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1097\/CM9.0000000000001327","article-title":"Identification of a Serum Three-MicroRNA Signature for Cervical Cancer Diagnosis","volume":"134","author":"Cao","year":"2021","journal-title":"Chin. Med. J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbrc.2018.09.102","article-title":"MiR-20a Inhibits the Killing Effect of Natural Killer Cells to Cervical Cancer Cells by Downregulating RUNX1","volume":"505","author":"Zhu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2018.11.043","article-title":"MicroRNA-20a Regulates Cell Proliferation, Apoptosis and Autophagy by Targeting Thrombospondin 2 in Cervical Cancer","volume":"844","author":"Zhou","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.biopha.2018.03.154","article-title":"Up-Regulation of MiR-20a by HPV16 E6 Exerts Growth-Promoting Effects by Targeting PDCD6 in Cervical Carcinoma Cells","volume":"102","author":"Liu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_84","first-page":"583","article-title":"MicroRNA-616 Induces Androgen-Independent Growth of Prostate Cancer Cells by Suppressing Expression of Tissue Factor Pathway Inhibitor TFPI-2","volume":"71","author":"Ma","year":"2011","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2311658","DOI":"10.1080\/01443615.2024.2311658","article-title":"Human Papillomavirus Type 16 E7 Promotes Cell Viability and Migration in Cervical Cancer by Regulating the MiR-23a\/HOXC8 Axis","volume":"44","author":"Chen","year":"2024","journal-title":"J. Obstet. Gynaecol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.02.026","article-title":"Plasma Levels of MiR-125b-5p and MiR-206 in Acute Ischemic Stroke Patients After Recanalization Treatment: A Prospective Observational Study","volume":"28","author":"He","year":"2019","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11239-023-02831-9","article-title":"The Potential Role of Micro-RNA 125b-5p Level in Predicting Outcome from Thrombolytic Therapy in Patients with Acute Ischemic Stroke","volume":"56","author":"Mostafa","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e12913","DOI":"10.1111\/cpr.12913","article-title":"Essential Functions of MiR-125b in Cancer","volume":"54","author":"Peng","year":"2021","journal-title":"Cell Prolif."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wang, X., Tang, S., Le, S.Y., Lu, R., Rader, J.S., Meyers, C., and Zheng, Z.M. (2008). Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002557"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/PDM.0b013e3181c4daaa","article-title":"Strong Inverse Correlation between MicroRNA-125b and Human Papillomavirus DNA in Productive Infection","volume":"19","author":"Nuovo","year":"2010","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/blood.2023022285","article-title":"High MicroRNA-145 Plasma Levels Are Associated with Decreased Risk of Future Incident Venous Thromboembolism: The HUNT Study","volume":"143","author":"Morelli","year":"2024","journal-title":"Blood"},{"key":"ref_92","first-page":"637","article-title":"van H.; Truong, V.; Li, Y.; G\u00e5din, J.R.; Tang, W.; et al. Genome-Wide Association Study with Additional Genetic and Post-Transcriptional Analyses Reveals Novel Regulators of Plasma Factor XI Levels","volume":"26","author":"Sennblad","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"107676","DOI":"10.1016\/j.pharmthera.2020.107676","article-title":"A Novel Rationale for Targeting FXI: Insights from the Hemostatic MicroRNA Targetome for Emerging Anticoagulant Strategies","volume":"218","author":"Nourse","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/bjc.2011.520","article-title":"The MiR-143\/-145 Cluster Regulates Plasminogen Activator Inhibitor-1 in Bladder Cancer","volume":"106","author":"Villadsen","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13402-016-0307-3","article-title":"MicroRNA-145 Modulates Epithelial-Mesenchymal Transition and Suppresses Proliferation, Migration and Invasion by Targeting SIP1 in Human Cervical Cancer Cells","volume":"40","author":"Sathyanarayanan","year":"2017","journal-title":"Cell Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.febslet.2015.01.037","article-title":"MicroRNA-145 Contributes to Enhancing Radiosensitivity of Cervical Cancer Cells","volume":"589","author":"Ye","year":"2015","journal-title":"FEBS Lett."},{"key":"ref_98","first-page":"3740","article-title":"MiR-145 Inhibits Cervical Cancer Progression and Metastasis by Targeting WNT2B by Wnt\/\u03b2-Catenin Pathway","volume":"12","author":"Li","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.repbio.2020.04.001","article-title":"Functional Implications of MiR-145\/RCAN3 Axis in the Progression of Cervical Cancer","volume":"20","author":"Zhang","year":"2020","journal-title":"Reprod. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/0963689719861063","article-title":"MiR-145 Contributes to the Progression of Cervical Carcinoma by Directly Regulating FSCN1","volume":"28","author":"Ma","year":"2019","journal-title":"Cell Transplant."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Silva, J., Tavares, V., Afonso, A., Garcia, J., Cerqueira, F., and Medeiros, R. (2023). Plasmatic MicroRNAs and Treatment Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer: A Hospital-Based Cohort Study and In Silico Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24109101"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ymeth.2012.09.015","article-title":"Assessing Sample and MiRNA Profile Quality in Serum and Plasma or Other Biofluids","volume":"59","author":"Blondal","year":"2013","journal-title":"Methods"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Shah, J.S., Soon, P.S., and Marsh, D.J. (2016). Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum MicroRNAs. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153200"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Tavares, V., Savva-Bordalo, J., Rei, M., Liz-Pimenta, J., Assis, J., Pereira, D., and Medeiros, R. (2024). Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour. Cancers, 16.","DOI":"10.3390\/cancers16132356"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Tsai, S.J., Ruan, Y.X., Lee, C.C., Lee, M.S., Chiou, W.Y., Lin, H.Y., Hsu, F.C., Su, Y.C., and Hung, S.K. (2012). The incidence of venous thromboembolism in cervical cancer: A nationwide population-based study. BMC Res. Notes, 5.","DOI":"10.1186\/1756-0500-5-316"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.thromres.2013.01.027","article-title":"Incidence of Venous Thromboembolism before Treatment in Cervical Cancer and the Impact of Management on Venous Thromboembolism after Commencement of Treatment","volume":"131","author":"Satoh","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Garg, P., Krishna, M., Subbalakshmi, A.R., Ramisetty, S., Mohanty, A., Kulkarni, P., Horne, D., Salgia, R., and Singhal, S.S. (2024). Emerging Biomarkers and Molecular Targets for Precision Medicine in Cervical Cancer. Biochim. Biophys. Acta Rev. Cancer, 1879.","DOI":"10.1016\/j.bbcan.2024.189106"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"156782","DOI":"10.1016\/j.cyto.2024.156782","article-title":"Inflammation and Thrombotic Risk in Late-Stage Cervical Cancer: An Exploratory Study of Coagulation and Cytokine Profiles in a South African Cohort","volume":"184","author":"Fourie","year":"2024","journal-title":"Cytokine"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9796\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:50:35Z","timestamp":1760035835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":108,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199796"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199796","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}